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Abstract Tissue inhibitor of metalloproteinases (TIMP-2) is a 
low molecular weight proteinase inhibitor capable of inhibiting 
activated matrix metailoproteinases (MMPs). TIMP-2 is found 
both free and in a 1:1 stoichiometric complex with the pro-enzyme 
form of MMP-2 (pro-MMP-2fFIMP-2 complex). We have 
measured the binding of recombinant TIMP-2 to intact HT-1080 
and MCF-7 cells. HT-1080 cells in suspension bound ~2Sl-labeled 
rTIMP-2 with a K d of 2.5 nM and 30,000 sites/cell. Monolayers 
of MCF-7 cells were similarly found to bind [12Sl]rTIMP-2 with 
a Kd of 1.6 nM and 25,000 sites/cell. Specific binding of MMP-2 
alone to HT-1080 cells was not observed; however, pro-MMP-21 
TIMP-2 complex was capable of binding to the surface of HT- 
1080 cells in a TIMP-2-dependent manner. Binding of rTIMP-2 
was not competed by the presence of TIMP-1. These results 
suggest hat rTIMP-2 alone binds directly to the cell surface of 
HT-1080 and MCF-7 cell lines, and TIMP-2 is capable of local- 
izing MMP-2 to the surface of HT-1080 cells via interaction with 
a specific binding site. 
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identified: TIMP-1, TIMP-2 and TIMP-3 [,~8]. TIMP-2 is a 
non-glycosylated, 192 amino acid protein of 21 kDa [4,5] which 
preferentially complexes with the pro-enzyme form of MMP-2, 
suggesting that it may selectively modulate activity of the en- 
zyme [9]. A cell surface MMP-2 activating species has been 
described in HT-1080 fibrosarcoma cells which is capable of 
processing pro-MMP-2 to active MMP-2 [10]. The cell surface 
activating species has been proposed to be MT-MMP, a re- 
cently discovered member of the matrix metalloprotinease fam- 
ily[l 1]. The role of TIMP-2 in modulating pro-MMP-2 activa- 
tion by these cells is not known. 
Previous reports have shown specific TIMP-I  binding to cell 
lines in culture [12,13]. A recent report shows that TIMP-2 is 
also capable of direct cell surface binding [14]. In this study we 
examined the cell surface interaction of TIMP-2 and MMP-2/ 
TIMP-2 complex with MCF-7 breast adenocarcinoma cells and 
HT-1080 fibrosarcoma cells. Our results show that both cell 
lines exhibit specific rTIMP-2 binding, and suggest hat TIMP- 
2 binding may be important in localizing MMP-2/TIMP-2 com- 
plex to the cell surface. 
2. Materials and methods 
I. Introduction 
Matrix metalloproteinases (MMPs) are a family of zinc-de- 
pendent enzymes involved in extracellular matrix (ECM) turn- 
over [1]. Members of the metalloproteinase family mediate 
ECM degradation during physiologic tissue remodeling, and 
have been implicated in a number of pathologic conditions 
including tumor invasion and osteoarthritis [2]. The regulation 
of MMPs is complex and occurs at many levels including gene 
expression, activation of secreted pro-enzyme forms, and inhi- 
bition of active enzyme forms [3]. MMP-2 (progelatinase A; 72 
kDa type IV collagenase) is secreted from many cell lines in 
culture as a 72 kDa pro-enzyme which must be processed ex- 
tracellularly to a 62 kDa active enzyme [2]. The active enzyme 
is capable of degrading several extracellular matrix components 
including type IV collagen and fibronectin [1]. 
Activity of MMPs can be modulated by interaction with 
specific proteinase inhibitors known as tissue inhibitors of met- 
alloproteinases (TIMPs). Three different TIMPs have been 
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Abbreviations: MMP, matrix metalloproteinase; TIMP, tissue inhibitor 
of metalloproteinase; rTIMP-2, recombinant TIMP-2: PBS, phosphate- 
buffered saline; BSA, bovine serum albumin; HEPES, 4-(2-hydroxy- 
ethyl)-l-piperazinethanesulfonic acid; SDS, sodium dodecyl sulfate; 
DMEM, Dulbecc'os modified eagles medium; FBS, fetal bovine serum; 
dpm, disintegrations per minute. 
2.1. Proteins 
Recombinant TIMP-2 (rTIMP-2) and C-terminally truncated TIMP- 
2 (3126 194) were prepared in a vaccinia virus mammalian cell expres- 
sion system, as previously described [15]. Purified rTIMP-2 was gener- 
ously provided by B. Bird, Oncologix Inc., Gaithersburg, MD. TIMP-1 
expressing CHO cells were obtained from Genetics Institute (Cam- 
bridge, MA) and TIMP-1 purified from conditioned media by affinity 
chromatography, pro-MMP-2/TIMP-2 complex was purified from 
A2058 conditioned media as previously described [5]. The TIMP-2 
C-terminal peptide, AWYRGAAPPKQEFLDIEDP, consisting of res- 
idues 176,194 of the mature TIMP-2 protein, was synthesized on a 
Biosearch 9600 peptide synthesizer and purified by reverse phase 
HPLC. 
2.2. Binding experiments 
rTIMP-2 and pro-MMP-2/TIMP-2 were iodinated using the lacto- 
peroxidase method with Enzymobead radio-iodination reagent (Bio- 
Rad), following the manufacturer's procedure to a specific activity of 
~5 X 106 cpm/,ug. 
Binding assays of ~2SI-labeled rTIMP-2 to HT-1080 cells (ATCC) in 
suspension were performed in triplicate as follows. Cells were grown 
to 80-90% confluency in DMEM supplemented with 10% FBS (Gibco 
BRL). Cells were then washed 3 times with cold PBS with 0.1% BSA 
in the absence of calcium, and incubated for 1 h in the same buffer. Cells 
were gently detached from the flask with a cell scraper, washed 3 times 
in calcium-flee PBS with 0.1% BSA, and resuspended in calcium con- 
taining PBS with 0.1% BSA. 10 nM ~25I-labeled rTIMP-2 was added to 
the cells for 3 h at 4°C in the presence or absence of 1 pM unlabeled 
rTIMP-2. In some experiments, 1 pM unlabeled TIMP-1, 1 pM pro- 
M M P-2/TI MP-2 complex, or 10 pM of the TIMP-2 C-terminus peptide 
was added to the cells for 15 min prior to the addition of labeled 
rT1MP-2. Cells were washed 3 times with PBS with 0.1% BSA with 
calcium and counted in a gamma-counter. Specific binding was calcu- 
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lated as the difference in bound 125I-labeled rTIMP-2 in the presence 
or absence of unlabeled rTIMP-2, TIMP-1, pro-MMP-2/TIMP-2 com- 
plex, or C-terminus TIMP-2 peptide. Similar experiments with 
~2SI-labeled rMMP-2 and pro-MMP-2/TIMP-2 complex were also per- 
formed. 
Binding assays were performed in triplicate with MCF-7 cells 
(ATCC) grown as a monolayer. Cells were first plated in a 24-well plate 
in DMEM supplemented with 10% FBS. After 1 day of culture, the cells 
were washed 3 times with DMEM containing 20 mM HEPES, 0.1% 
BSA. Saturation experiments were performed for 3 h at 22°C with 
various concentrations of [125I]TIMP-2 (0.2-20 nM) in the presence or
absence of 2 ¢tM unlabeled rTIMP-2. Cell monolayers were then 
washed 3times with PBS with 0.1% BSA, lysed with 0.1% SDS in 0.5 M 
NaOH, and the bound radioactivity was measured by gamma- 
counting. For the analysis of binding data, best fit-curves were deter- 
mined using the MLAB program [16,17] with equations as previously 
described [18]. 
2.3. Electrophoresis 
~25I-Labeled rTIMP-2 was incubated with HT-1080 cells in the pres- 
ence or absence of 100-fold excess unlabeled rTIMP-2. Cells were 
washed 3times with calcium containing PBS, and solubilized incalcium 
containing PBS with 1% Triton X-100 at 4°C in the presence of pro- 
teinase inhibitors. A portion of the initial supernatant of the sample 
with excess unlabeled TIMP-2 was added to the same cell preparation 
after solubilization such that the two samples (i.e. labeled rTIMP-2 + 
excess unlabeled rTIMP-2) contained equivalent amounts of labeled 
rTIMP-2. Solubilized cells were centrifuged ina Beckman centrifuge at
100,000 ×g for 1 h at 4°C. Supernatants were analyzed by electropho- 
resis and autoradiography using a 4~20% gradient polyacrylamide g l 
under non-denaturing, non-reducing conditions. 
3. Results 
Specific binding of ]251-labeled rTIMP-2 to HT-1080 and 
MCF-7 cells was observed. The time course for the binding of 
TIMP-2 to an MCF-7 cell monolayer shows that equilibrium 
is reached at 3 h at 22°C (Fig. 1). The concentration depend- 
ence of TIMP-2 binding to the MCF-7 cells demonstrated spe- 
cific and saturable binding characteristics (Fig. 2A). Scatchard 
analysis of binding data showed the existence of a single class 
of high-affinity binding sites with a K d of 1.6 nM, and 25,000 
sites per cell (Fig. 2B, Table 1). Similar results were obtained 
with isolated membrane preparations indicating the binding 
site localizes to the plasma membrane (results not shown). 
Analysis of t251-1abeled rTIMP-2 binding to HT-1080 cells in 
suspension was performed at 22°C for 3 h based on the TIMP-2 
binding experiments performed with MCF-7 cells. Again, the 
concentration dependence of this binding showed specific and 
saturable binding of TIMP-2 to the HT-1080 cells (data not 
shown). Scatchard analysis of the TIMP-2 binding to HT-1080 
cells in suspension gave results (Table 1) that are in excellent 
agreement with those obtained for MCF-7 cell monolayers. 
HT-1080 cells had a dissociation constant for TIMP-2 binding 
Kd = 2.5 nM, with approximately 30,000 sites per cell. 
Based on the Scatchard analysis of binding, further explora- 
Table l 
MCF-7 and HT-1080 cell binding data 
Cell line TIMP-2 binding MMP-2 binding 
K d Sites/cell 
HT-1080 2.5 nM 30,000 Mediated by TIMP-2 
MCF-7 1.6 nM 25,000 Direct? 
The two cell lines show similar TIMP-2 binding characteristics, but 
differ in the binding and activation of MMP-2. 
,-, 15 
s 
~, 0 
Incubation Time (hours) 
Fig. 1. Time course of binding of rTIMP-2 to MCF-7 cells. Steady-state 
binding was achieved after 3 h of incubation as described insection 2. 
tion of the nature of the TIMP-2 binding to HT-1080 cells was 
performed using 10 nM concentration f ~25I-labeled rTIMP-2. 
Addition of 100-fold molar excess of pro-MMP-2/TIMP-2 
complex, or C-terminally truncated TIMP-2 completely abol- 
ished binding of rTIMP-2 to the cells (Fig. 3). Under these 
conditions non-specific binding of TIMP-2 was minimized to 
less than 15% of total binding. The specific binding of 
~25I-labeled rTIMP shown in Fig. 3 represents the difference 
between total ]25I-labeled rTIMP bound (3823 + 35 dpm) and 
]25I-labeled rTIMP bound in the presence of a 100-fold molar 
excess of unlabeled rTIMP-2 (615 + 14 dpm). However, compe- 
tition with 100-fold molar excess of TIMP-1 did not affect 
rTIMP-2 binding (Fig. 3) nor did the addition of 1000-fold 
molar excess of the linear peptide, AWYRGAAPPK- 
QEFLDIEDP, representing the C-terminus of TIMP-2 (Fig. 3). 
These findings are consistent with the known interactions of 
pro-MMP-2 and TIMP-2 which are mediated by direct C-ter- 
minal interactions, and suggest hat the cell-surface binding 
domain of TIMP-2 is located elsewhere within the TIMP-2 
molecule. 
175 " I-Labeled pro-MMP-2/TIMP-2 complex exhibited specific 
binding to HT-1080 cells in suspension, but L25I-labeled pro- 
rMMP-2 alone did not (data not shown). The binding of 
~25I-labeled pro-MMP-2/TIMP-2 complex was not affected by 
the presence of 100-fold molar excess of TIMP-1, but was 
completely abolished in the presence of excess rTIMP-2, or C- 
terminally truncated TIMP-2 (Fig. 4). The binding of both 
components of the ~25I-labeled pro-MMP-2/TIMP-2 complex 
to the cells was confirmed by SDS-PAGE and autoradiography 
(results not shown). These results are again consistent with the 
cell-surface binding of TIMP-2 being mediated by peptide se- 
quence that is not located in the final C-terminal peptide loop 
or tail of the TIMP-2 peptide. 
Native gel electrophoresis performed on solubilized HT-1080 
cells after binding with labeled rTIMP-2 showed a specific shift 
in mobility of the rTIMP-2 (Fig. 5). Under non-denaturing, 
non-reducing conditions, rTIMP-2 alone migrates as a diffuse 
band (Fig. 5; lane 1). Electrophoresis performed after HT-1080 
binding and solubilization shows the labeled rTIMP-2 shifted 
to a compact band which migrated less distance in the gel, due 
to association with the HT-1080 binding moiety (Fig. 5; lane 
2). Competition with excess unlabeled rTIMP-2 dissociates the 
125I-labeled binding complex and the ~25I-labeled rTIMP-2 mi- 
grates with the free rTIMP-2 (Fig. 5; lane 3). 
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Fig. 2. Steady-state binding of ]25I-labeled rTIMP-2 to monolayers of
MCF-7 cells. Binding was carried out in triplicate using various concen- 
trations of ~25I-labeled rTIMP-2 for 3 h at 22°C. Specific binding was 
calculated as the difference in bound radioactivity in the presence or 
absence of excess unlabeled rTIMP-2. Fig. 2. (A) Binding curve show- 
ing saturation of binding in MCF7 monolayers ( pecific activity of 
~251-1abeled rTIMP-2 = 4,800 cpm/ng; each well contained 2.1 × 105 
cells per well). B: Scatchard plot of the binding data. Analysis of the 
data indicated MCF-7 cells contain 25,000 sites/cell and bind to 
TIMP-2 with a Kd of 1.6 nm. 
4. Discussion 
In the present study we describe the identification of a bind- 
ing site for rTIMP-2 on HT-1080 fibrosarcoma nd MCF-7 
breast adenocarcinoma cells. Similar binding characteristics 
were observed with both cell types. TIMP-2 dependent binding 
of pro-MMP-2/TIMP-2 complex to HT-1080 cells was also 
observed, representing a mechanism for localizing MMP-2 to 
the cell surface. The TIMP-2-mediated binding of MMP-2 to 
HT-1080 cells and apparent independent binding of TIMP-2 
and MMP-2 [18] directly to MCF-7 cells may represent two 
models of metalloproteinase cell surface interaction (Table 1). 
HT-1080 cells produce endogenous MMP-2 and TIMP-2, 
while MCF-7 cells produce only low levels of endogenous 
TIMP-2. Both MCF7 and HTI080 cells are capable of directly 
binding TIMP-2 and pro-MMP-2/TIMP-2 complex, and we 
have shown previously that MCF-7 cells can possibly bind 
MMP-2 directly [19]. However, in these earlier experiments we 
did not directly asses MCF-7 production of endogenous TIMP- 
2 which could mediate the binding of exogenous MMP-2. Fur- 
thermore, the exogenous MMP-2 preparation used in these 
studies was purified from the conditioned media of BeWo cells 
and contains pro-MMP-2/TIMP-2 complex. The similarity of 
the dissociation constants and number of binding sites reported 
previously for MMP-2 on MCF-7 cells and in the present study 
for TIMP-2 suggests that TIMP-2 mediated binding of MMP-2 
in MCF-7 cells is a distinct possibility. Although we cannot 
presently rule out that MMP-2 may bind to some cells inde- 
pendently ofTIMP-2. HT-1080 cells cannot bind MMP-2 alone 
and compared to MCF-7 cells they are unique in their ability 
to synthesize, secrete and activate the enzyme. 
In vivo, cells like HT-1080 would be capable of producing 
and activating pro-MMP-2 and/or pro-MMP-2/TIMP-2 com- 
plex independently. On the other hand, cells like MCF-7 would 
bind the active enzyme, or active enzyme complex to the cell 
surface and effect degradation of ECM molecules. This model 
is consistent with in vivo studies howing that stromal fibro- 
blasts produce MMP-2 mRNA, but the protein product is 
localized to nearby epithelial cells [20-22]. The significance of 
producing active MMP-2 versus active MMP-2/TIMP-2 com- 
plex is unclear. Activated MMP-2 alone is more proteolytically 
active than MMP-2/TIMP-2 complex, but has a shorter half- 
life than enzyme complex due to autolysis [23]. The cells could 
potentially produce short bursts of high proteolytic activity by 
secreting and activating MMP-2 alone, as opposed to activating 
MMP-2/TIMP-2 complex and producing sustained but lower 
levels of proteolytic activity. 
Binding of free TIMP-2 may also serve an important protec- 
tive function for cells in the vicinity of ECM degradation. 
Placement of the inhibitor at the cell surface may allow stromal 
or epithelial cells to actively participate in tissue remodeling 
without extensive degradation of cell surface molecules. Nor- 
mal wound healing, for example, consists of sequential steps of 
tissue resorption and regeneration in which stromal and epithe- 
lial cells are in close proximity to regions of ECM undergoing 
extensive proteolysis. Unrestricted proteolysis of cellular pro- 
teins would presumably be deleterious to cells mediating this 
process. Localization of free TI M P-2 to the membranes of these 
cells would be an effective inhibitor of cell surface proteolysis 
mediated by any members of the MMP class. 
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Fig. 3. Specific binding of rTIMP-2 to HT-1080 cells in suspension. 
Binding was inhibited by 100 fold molar excess of C-terminally trun- 
cated TIMP-2, or 100-fold molar excess of MMP-2/TIMP-2 complex. 
The C-terminally truncated TIMP-2 is missing the domain responsible 
for interaction with pro-MMP-2. 100-fold molar excess TIMP-1, and 
1000-fold molar excess of TIMP-2 C-terminal peptide did not demon- 
strate significant competition for TIMP-2 binding. 
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TIMP-2 is a bifunctional protein with growth stimulatory as 
well as proteinase inhibitory activity. An additional function of 
TIMP-2 cell surface binding may be in mediating cell prolifer- 
ation. Several previous reports have shown that both TIMP-1 
and TIMP-2 can stimulate a proliferative response, and recent 
findings suggest hat rTIMP-2 is growth stimulatory for HT- 
1080 cells (Corcoran, M.L. and Stetler-Stevenson, W.G., un- 
published results). Cell surface binding sites for TIMP-1 and 
TIMP-2 have been reported, however, cell surface receptors for 
these molecules have not been isolated [12-14]. HT-1080 cells 
show increased cAMP levels when treated with rT1MP-2 sug- 
gesting that TIMP-2 modulation of cell growth is mediated via 
a receptor/second messenger system (Corcoran, M.L. and 
Stetler-Stevenson, W.G., unpublished results). The relationship 
between the binding moiety identified in the present study and 
the putative rTIMP-2 receptor esponsible for HT-1080 cell 
proliferation is presently not known. Thus, TIMP-2 is capable 
of mediating several important physiologic processes involving 
cellular interactions with the ECM. In normal physiologic proc- 
esses such as tissue remodeling and repair, TIMP-2 has the 
potential to modulate MMP-2 activity during ECM degrada- 
tion, protect cell surface molecules from extensive degradation, 
inhibit all active MMP's after sufficient ECM degradation has 
occurred, and stimulate proliferation of fibroblasts during tis- 
sue reconstitution. 
Two binding sites on MMP-2 have been described for TIMP- 
2 [9,24,25]. The C-terminal region of TIMP-2 binds to the 
C-terminus of pro-MMP-2 to form the pro-MMP-2/TIMP-2 
complex, and the N-terminal region of T1MP-2 can interact 
with the active site of the enzyme to inhibit proteolysis [9,23 
26]. The results of the present study suggest that a third domain 
in rTIMP-2 mediates the binding to HT-1080 cells. C-Termi- 
nally truncated TIMP-2 inhibited binding of labeled rTIMP-2 
to HT-1080 cells, and the TIMP-2 C-terminus peptide did not 
inhibit binding suggesting that TIMP-2 does not bind to HT- 
1080 cells via the C-terminal region. Since the HT-1080 binding 
site is capable of binding TIMP-2, but not TIMP-1, we can 
postulate that the binding moiety is not an active MMP which 
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Fig. 4. Specific binding ofpro-MMP-2 and pro-MMP/TIMP-2 complex 
to HT-1080 cells in suspension. Binding of th pro-MMP-2/TIMP-2 
complex was competed with both 100-fold molar excess TIMP-2, as 
well as 100-fold molar excess of C-terminally truncated TIMP-2. Excess 
TIMP-1 did not inhibit binding of the pro-MMP-2/TIMP-2 complex. 
Binding of complex was not competed by the addition of cold 
pro-MMP-2 and direct binding of [~25I]pro-MMP-2 alone was not 
observed. 
rTIMP-2/HT- 1080 
Complex 
rTIMP-2 
Fig. 5. Electrophoresis of TIMP-2-cell surface complex. Poly- 
acrylamide gel electrophoresis analysis of TIMP-2 bound to HT-1080 
cells followed by solubilization with 1% triton X-100. Lanes represent: 
(1) radiolabeled rTIMP-2 alone, (2) radiolabeled rTIMP-2 bound to 
solubilized HT-1080 cells, and (3) radiolabeled rTIMP-2 bound to sol- 
ubilized HT-1080 cells in the presence of excess unlabeled rTIMP-2. 
Electrophoresis was run under non-denaturing, non-reducing condi- 
tions. The shift in electrophoretic mobility observed in lane 2 suggests 
the rTIMP-2 binds to a specific HT-1080 cell surface molecule. 
is interacting with the N-terminal inhibitory domain of TIMP- 
2. All members of the MMP family to date are capable of being 
inhibited by both TIMP-1 and TIMP-2 [1,26]. Thus, interaction 
of TIMP-2 with the HT-1080 cell surface binding site is most 
likely mediated by a third functional domain in the inhibitor. 
The selective binding of TIMP-2 to HT-1080 cells also suggests 
that TIMP-2 and TIMP-1, which are closely related proteins, 
possess distinct cell-surface binding domains. 
In summary, we describe a binding site for rTIMP-2 on the 
surface of two human cell lines. The binding site may be impor- 
tant in mediating several TIMP-2 dependent actions including 
cell proliferation, and cell surface modulation/localization of 
MMP-2. 
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